| Literature DB >> 20152025 |
Jenny Zetterblad1, Hong Qian, Sasan Zandi, Robert Månsson, Anna Lagergren, Frida Hansson, David Bryder, Nils Paulsson, Mikael Sigvardsson.
Abstract
BACKGROUND: The use of functional genomics has largely increased our understanding of cell biology and promises to help the development of systems biology needed to understand the complex order of events that regulates cellular differentiation in vivo. One model system clearly dependent on the integration of extra and intra cellular signals is the development of B-lymphocytes from hematopoietic stem cells in the bone marrow. This developmental pathway involves several defined differentiation stages associated with specific expression of genes including surface markers that can be used for the prospective isolation of the progenitor cells directly from the bone marrow to allow for ex vivo gene expression analysis. The developmental process can be simulated in vitro making it possible to dissect information about cell/cell communication as well as to address the relevance of communication pathways in a rather direct manner. Thus we believe that B-lymphocyte development represents a useful model system to take the first steps towards systems biology investigations in the bone marrow.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20152025 PMCID: PMC2830985 DOI: 10.1186/1471-2164-11-108
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Analysis of communication pathways for Long Term Hematopoietic Stem Cells (LT-HSC)
| Gene expressed in LT-HSC | Mean Intensity | Corresponding gene in stroma | Mean Intensity | NIH3T3 | Osteoblasts |
|---|---|---|---|---|---|
| activin receptor IIB | 267 | bone morphogenetic protein 4 | 1335 | 66 | 252 |
| bone morphogenetic protein 4 | 169 | bone morphogenetic protein receptor, type 1A | 497 | 274 | 384 |
| chemokine (C-X-C motif) receptor 4 | 372 | chemokine (C-X-C motif) ligand 12 | 12222 | 23 | 798 |
| epidermal growth factor receptor | 149 | epiregulin | 422 | 288 | 153 |
| insulin-like growth factor 2 | 105 | insulin-like growth factor 2 receptor | 535 | 1772 | 1704 |
| Integrin alpha 4 | 1675 | junction adhesion molecule 2 | 201 | 16 | 26 |
| integrin beta 1 (fibronectin receptor beta) | 307 | junction adhesion molecule 2 | 201 | 16 | 26 |
| integrin beta 2 | 558 | junction adhesion molecule 3 | 152 | 42 | 204 |
| jagged 2 | 222 | Notch gene homolog 3 (Drosophila) | 367 | 161 | 48 |
| oncostatin M | 115 | oncostatin M receptor | 1151 | 1349 | 131 |
| epidermal growth factor receptor | 149 | transforming growth factor alpha | 261 | 13 | 21 |
| Integrin alpha 4 | 1675 | vascular cell adhesion molecule 1 | 692 | 182 | 929 |
| integrin beta 1 (fibronectin receptor beta) | 307 | vascular cell adhesion molecule 1 | 692 | 182 | 929 |
| integrin beta 7 | 329 | vascular cell adhesion molecule 1 | 692 | 182 | 929 |
| kinase insert domain protein receptor | 311 | vascular endothelial growth factor A | 179 | 1006 | 169 |
Analysis of communication pathways for Multipotent progenitors (MPP)
| Gene expressed in MPP | Mean Intensity | Corresponding gene in stroma | Mean Intensity | NIH3T3 | Osteoblasts |
|---|---|---|---|---|---|
| activin receptor IIB | 183 | bone morphogenetic protein 4 | 1335 | 66 | 252 |
| Bone morphogenetic protein 15 | 413 | bone morphogenetic protein receptor, type 1A | 327 | 377 | 287 |
| bone morphogenetic protein 4 | 112 | bone morphogenetic protein receptor, type 1A | 327 | 377 | 287 |
| chemokine (C-X-C motif) receptor 4 | 264 | chemokine (C-X-C motif) ligand 12 | 12222 | 23 | 798 |
| epidermal growth factor receptor | 231 | epiregulin | 422 | 288 | 153 |
| insulin-like growth factor 2 | 271 | insulin-like growth factor 2 receptor | 535 | 1772 | 1704 |
| interleukin 1 receptor, type I | 123 | interleukin 1 receptor antagonist | 3515 | 16 | 10 |
| integrin alpha 4 | 278 | junction adhesion molecule 2 | 201 | 16 | 26 |
| integrin beta 1 (fibronectin receptor beta) | 180 | junction adhesion molecule 2 | 201 | 16 | 26 |
| integrin beta 2 | 507 | junction adhesion molecule 3 | 152 | 42 | 204 |
| oncostatin M | 157 | oncostatin M receptor | 1151 | 1349 | 131 |
| epidermal growth factor receptor | 231 | transforming growth factor alpha | 261 | 13 | 21 |
| integrin alpha 4 | 278 | vascular cell adhesion molecule 1 | 692 | 182 | 929 |
| integrin beta 1 (fibronectin receptor beta) | 180 | vascular cell adhesion molecule 1 | 692 | 182 | 929 |
Analysis of communication pathways for Lymphoid primed Multipotent Progenitors (LMPP)
| Gene expressed in LMPP | Mean Intensity | Corresponding gene in stroma | Mean Intensity | NIH3T3 | Osteoblasts |
|---|---|---|---|---|---|
| activin receptor IIA | 131 | bone morphogenetic protein 4 | 1335 | 66 | 252 |
| activin A receptor, type 1 | 107 | bone morphogenetic protein 4 | 1335 | 66 | 252 |
| bone morphogenetic protein 4 | 277 | bone morphogenetic protein receptor, type 1A | 497 | 274 | 384 |
| epidermal growth factor receptor | 189 | epiregulin | 422 | 288 | 153 |
| insulin-like growth factor 2 | 139 | insulin-like growth factor 2 receptor | 535 | 1772 | 1704 |
| interleukin 2 receptor, gamma chain | 2115 | interleukin 7 | 189 | 92 | 255 |
| oncostatin M | 178 | oncostatin M receptor | 1151 | 1349 | 131 |
| chemokine (C-X-C motif) receptor 4 | 290 | chemokine (C-X-C motif) ligand 12 | 12222 | 23 | 798 |
| epidermal growth factor receptor | 189 | transforming growth factor alpha | 261 | 13 | 21 |
| tumor necrosis factor | 102 | tumor necrosis factor receptor superfamily, member 1a | 1974 | 959 | 1143 |
| tumor necrosis factor | 102 | tumor necrosis factor receptor superfamily, member 1b | 108 | 721 | 108 |
| integrin alpha 4 | 268 | vascular cell adhesion molecule 1 | 692 | 182 | 929 |
| integrin beta 7 | 453 | vascular cell adhesion molecule 1 | 692 | 182 | 929 |
| integrin beta 1 (fibronectin receptor beta) | 173 | vascular cell adhesion molecule 1 | 692 | 182 | 929 |
| integrin beta 1 (fibronectin receptor beta) | 173 | junction adhesion molecule 2 | 201 | 16 | 26 |
| integrin alpha 4 | 268 | junction adhesion molecule 2 | 201 | 16 | 26 |
| integrin beta 2 | 484 | junction adhesion molecule 3 | 152 | 42 | 204 |
Analysis of communication pathways for Common Lymphoid Progenitors (CLP)
| Gene expressed in CLP | Mean Intensity | Corresponding gene in stroma | Mean Intensity | NIH3T3 | Osteoblasts |
|---|---|---|---|---|---|
| interleukin 2 receptor, gamma chain | 3021 | interleukin 7 | 189 | 92 | 255 |
| chemokine (C-X-C motif) receptor 4 | 2121 | chemokine (C-X-C motif) ligand 12 | 12222 | 23 | 798 |
| integrin alpha 4 | 1982 | vascular cell adhesion molecule 1 | 692 | 182 | 929 |
| integrin alpha 4 | 1982 | junction adhesion molecule 2 | 201 | 16 | 26 |
| integrin beta 2 | 920 | junction adhesion molecule 3 | 152 | 42 | 204 |
| Bone morphogenetic protein 15 | 645 | bone morphogenetic protein receptor, type 1A | 497 | 274 | 384 |
| chemokine (C-C motif) receptor 9 | 443 | chemokine (C-C motif) ligand 25 | 123 | 55 | 100 |
| insulin-like growth factor 2 | 282 | insulin-like growth factor 2 receptor | 535 | 1772 | 1704 |
| epidermal growth factor receptor | 193 | epiregulin | 422 | 288 | 153 |
| epidermal growth factor receptor | 193 | transforming growth factor alpha | 261 | 13 | 21 |
| interleukin 1 receptor, type I | 180 | interleukin 1 receptor antagonist | 3515 | 16 | 10 |
| activin receptor IIB | 166 | bone morphogenetic protein 4 | 1335 | 66 | 252 |
| interleukin 1 receptor, type II | 127 | interleukin 1 receptor antagonist | 3515 | 16 | 10 |
| oncostatin M | 112 | oncostatin M receptor | 1151 | 1349 | 131 |
Analysis of communication pathways for Granolocyte Monocyte Progenitors (GMP)
| Gene expressed in GMP | Mean Intensity | Corresponding gene in stroma | Mean Intensity | NIH3T3 | Osteoblasts |
|---|---|---|---|---|---|
| chemokine (C-X-C motif) receptor 4 | 768 | chemokine (C-X-C motif) ligand 12 | 12222 | 23 | 798 |
| epidermal growth factor receptor | 182 | epiregulin | 422 | 288 | 153 |
| interleukin 2 receptor, gamma chain | 869 | interleukin 7 | 189 | 92 | 255 |
| integrin alpha 4 | 171 | junction adhesion molecule 2 | 201 | 16 | 26 |
| integrin beta 1 (fibronectin receptor beta) | 122 | junction adhesion molecule 2 | 201 | 16 | 26 |
| integrin beta 2 | 969 | junction adhesion molecule 3 | 152 | 42 | 204 |
| epidermal growth factor receptor | 182 | transforming growth factor alpha | 261 | 13 | 21 |
| integrin alpha 4 | 171 | vascular cell adhesion molecule 1 | 692 | 182 | 929 |
| integrin beta 1 (fibronectin receptor beta) | 122 | vascular cell adhesion molecule 1 | 692 | 182 | 929 |
| neuropilin 1 | 120 | vascular endothelial growth factor A | 179 | 1006 | 169 |
| neuropilin 1 | 120 | vascular endothelial growth factor B | 174 | 191 | 639 |
Analysis of communication pathways for progenitor B-cells (Pro-B)
| Gene expressed in ProB | Mean Intensity | Corresponding gene in stroma | Mean Intensity | NIH3T3 | Osteoblasts |
|---|---|---|---|---|---|
| activin receptor IIA | 139 | bone morphogenetic protein 4 | 1335 | 66 | 252 |
| activin receptor IIB | 178 | bone morphogenetic protein 4 | 1335 | 66 | 252 |
| CD28 antigen | 439 | CD80 antigen | 462 | 38 | 71 |
| epidermal growth factor receptor | 193 | Epiregulin | 422 | 288 | 153 |
| insulin-like growth factor 2 | 113 | insulin-like growth factor 2 receptor | 535 | 1772 | 1704 |
| interleukin 2 receptor, gamma chain | 3348 | interleukin 7 | 189 | 92 | 255 |
| L1 cell adhesion molecule | 596 | neural cell adhesion molecule 1 | 129 | 740 | 545 |
| oncostatin M | 143 | oncostatin M receptor | 1151 | 1349 | 131 |
| platelet derived growth factor, B polypeptide | 122 | platelet derived growth factor receptor, alpha polypeptide | 2140 | 1066 | 445 |
| platelet derived growth factor, B polypeptide | 122 | platelet derived growth factor receptor, beta polypeptide | 1829 | 505 | 1782 |
| chemokine (C-C motif) receptor 2 | 141 | chemokine (C-C motif) ligand 2 | 239 | 3362 | 362 |
| chemokine (C-C motif) receptor 9 | 376 | chemokine (C-C motif) ligand 25 | 123 | 55 | 100 |
| chemokine (C-X-C motif) receptor 4 | 702 | chemokine (C-X-C motif) ligand 12 | 12222 | 23 | 798 |
| epidermal growth factor receptor | 193 | transforming growth factor alpha | 261 | 13 | 21 |
| integrin alpha 4 | 413 | vascular cell adhesion molecule 1 | 692 | 182 | 929 |
| integrin beta 7 | 2879 | vascular cell adhesion molecule 1 | 692 | 182 | 929 |
| integrin beta 1 (fibronectin receptor beta) | 130 | vascular cell adhesion molecule 1 | 692 | 182 | 929 |
| neuropilin 1 | 333 | vascular endothelial growth factor A | 275 | 1872 | 387 |
| kinase insert domain protein receptor | 389 | vascular endothelial growth factor A | 275 | 1872 | 387 |
| integrin beta 1 (fibronectin receptor beta) | 130 | junction adhesion molecule 2 | 201 | 16 | 26 |
| integrin alpha 4 | 413 | junction adhesion molecule 2 | 201 | 16 | 26 |
| integrin beta 2 | 4429 | junction adhesion molecule 3 | 152 | 42 | 204 |
Analysis of communication pathways for pre-B cells (pre-B)
| Gene expressed in PreB | Mean Intensity | Corresponding gene in stroma | Mean Intensity | NIH3T3 | Osteoblasts |
|---|---|---|---|---|---|
| chemokine (C-X-C motif) receptor 4 | 1526 | chemokine (C-X-C motif) ligand 12 | 12222 | 23 | 798 |
| epidermal growth factor receptor | 177 | Epiregulin | 422 | 288 | 153 |
| interleukin 2 receptor, gamma chain | 2147 | interleukin 7 | 189 | 92 | 255 |
| integrin alpha 4 | 199 | junction adhesion molecule 2 | 201 | 16 | 26 |
| integrin beta 2 | 1438 | junction adhesion molecule 3 | 152 | 42 | 204 |
| oncostatin M | 101 | oncostatin M receptor | 1151 | 1349 | 131 |
| epidermal growth factor receptor | 177 | transforming growth factor alpha | 261 | 13 | 21 |
| integrin alpha 4 | 199 | vascular cell adhesion molecule 1 | 692 | 182 | 929 |
Analysis of communication pathways for mature B-cells (B-cells)
| Gene expressed in MatureB | Mean Intensity | Corresponding gene in stroma | Mean Intensity | NIH3T3 | Osteoblasts |
|---|---|---|---|---|---|
| chemokine (C-X-C motif) receptor 4 | 1275 | chemokine (C-X-C motif) ligand 12 | 12222 | 23 | 798 |
| epidermal growth factor receptor | 145 | Epiregulin | 422 | 288 | 153 |
| interleukin 2 receptor, gamma chain | 2746 | interleukin 7 | 189 | 92 | 255 |
| Integrin alpha 4 | 1640 | junction adhesion molecule 2 | 201 | 16 | 26 |
| integrin beta 1 (fibronectin receptor beta) | 235 | junction adhesion molecule 2 | 201 | 16 | 26 |
| integrin beta 2 | 1781 | junction adhesion molecule 3 | 152 | 42 | 204 |
| lymphotoxin A | 540 | lymphotoxin B receptor | 965 | 285 | 519 |
| transforming growth factor, beta 1 | 718 | Similar to Ornithine decarboxylase (ODC) | 197 | 146 | 14 |
| epidermal growth factor receptor | 145 | transforming growth factor alpha | 261 | 13 | 21 |
| transforming growth factor, beta 1 | 718 | transforming growth factor, beta receptor II | 171 | 85 | 253 |
| transforming growth factor, beta 1 | 718 | transforming growth factor, beta receptor III | 3653 | 3429 | 1152 |
| lymphotoxin A | 540 | tumor necrosis factor receptor superfamily, member 1a | 1974 | 959 | 1143 |
| lymphotoxin A | 540 | tumor necrosis factor receptor superfamily, member 1b | 108 | 721 | 108 |
| Integrin alpha 4 | 1640 | vascular cell adhesion molecule 1 | 692 | 182 | 929 |
| integrin beta 1 (fibronectin receptor beta) | 235 | vascular cell adhesion molecule 1 | 692 | 182 | 929 |
| integrin beta 7 | 942 | vascular cell adhesion molecule 1 | 692 | 182 | 929 |
Tables 1, 2, 3, 4, 5, 6, 7 and 8. Receptor ligand pairs identified as possible means of communication between a model stroma cell line OP9 and sorted hematopoietic cells from the mouse bone marrow. Expression values observed in fibroblastic NIH3T3 and osteoblastic MC3T3 cells are included to allow for the identification of stromal cell specific interactions. The diagram only display receptor ligand pairs were genes on the hematopoietic array as well as of the stromal cells arrays have a normalized expression value above 100. Full lists of potential interactions can be found in Additional files 2, 3, 4, 5, 6, 7, 8 and 9. For sorted cells as well as OP9 the value is a mean out of 2 experiments for complete list of genes for each cell type see Additional files 2, 3, 4, 5, 6, 7, 8 and 9.
Figure 1Differential ability of OP9 and NIH3T3 cells to stimulate B-cell development from hematopoetic progenitor cells. Representative FACS plots of the cells generated after 14 days of incubation of 100 LSK cells on OP9 or NIH3T3 cells with the indicated addition of cytokines. The cells were analyzed with regard to the expression of CD19, B220, and MAC1 as indicated in the diagrams. The numbers in the panels represents average percentages of different cell subsets obtained under the defined conditions after analysis of at least three independent experiments.
Figure 2BNP4 stimulates B-cell development from early bone marrow progenitor cells. Diagrams displaying the cellular composition of cultures as judged by FACS analysis of B220, CD19 and MAC-1 surface expression obtained by in vitro differentiation of 100 LSK cells. The progenitors were incubated for 14 days with either OP9 or NIH3T3 cells and the indicated cytokines. Each dot in the diagrams represents one well and data are collected from at least three independent experiments (n = 13-18). Line indicates the average of all the analyzed wells and the P values has been calculated as compared to the cellular composition obtained on NIH3T3 cells with the addition of FL and IL7.
Figure 3B-cell progenitors modulate the behavior of OP9 stromal cells . Panel (A-B) display pictures of OP-9 cells grown in parallel cultures with either conditioned media (A) or in direct contact with pro-B cells (B) generated by in vitro differentiation of LSK cells. The pictures are taken from the same six well tissue culture plates with 200 times amplification and under the same light conditions (Leica DFC290). The black bar indicates 100 μM. Panel (C) shows a representative sorting experiment where trypsin/EDTA treated co-cultures of OP9S and pro-B cells are separated based on forward scatter and Strawberry expression. Panel (D) display a cluster analysis of RMA normalized gene expression patterns in OP9S cells incubated with either conditioned media or the pre-B cell line 230-238. The analysis displays genes with an expression level above 100 and with at least 5-fold difference in expression in the two experiments with P-value < 0.05. Red indicates high and blue low expression.
Figure 4Co-culture of cell lines representing different hematopoietic lineages induces differential gene expression patterns in OP9 cells. The diagrams display HPRT normalized Q-PCR data from OP9S cells generated by co-incubation of hematopoietic cell lines or filtered media from the parallel co-culture experiments (OP9S). The expression pattern in the control cells were set to one for each of the Nov (Black bar), SpiB (White bar) or Cxcl10 (Striped bars) and the relative induction/reduction is indicated. Error bars indicate experimental variation in one out of two or three experiments.